• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Transcend Medical touts data, plans FDA filing for CyPass glaucoma stent

Transcend Medical touts data, plans FDA filing for CyPass glaucoma stent

May 6, 2015 By Brad Perriello

Transcend Medical touts data, plans FDA filing for CyPass glaucoma stent

Transcend Medical yesterday said it plans to file for pre-market approval from the FDA for its CyPass glaucoma micro-stent after its Compass clinical trial showed "sustained and consistent positive results through 2 years."

Menlo Park, Calif.-based Transcend said it plans to file for the PMA during the 2nd half of the year, noting that the Compass trial met its primary endpoint of 20% or greater reduction in intraocular pressure. The Compass trial, of more than 500 patients with mild to moderate glaucoma, compared CyPass plus cataract surgery with cataract surgery alone.

"The results are positive and highly statistically significant across all endpoints at both 1 and 2 years," marketing & medical affairs director Ravi Pamnani told MassDevice.com via email, noting that CyPass is the 1st minimally invasive glaucoma stent to achieve this milestone.

"We are planning on releasing the detailed data, as well as submitting to peer-reviewed publications, following our PMA application to FDA later this year," Pamnani wrote.

CyPass is designed to be implanted in the supraciliary space to help drain ocular fluid and reduce pressure within the eye. Transcend said the Compass trial also met its secondary endpoints with "statistically significantly greater effectiveness" than cataract surgery alone.

"We are very pleased with the results of the Compass trial," president & CEO Brian Walsh said in prepared remarks. "We are committed to a rigorous, evidence-based approach to evaluating the CyPass micro-stent, and the Compass study is a testament to this mission. We believe the CyPass technology has the potential to help the millions of patients who suffer from glaucoma worldwide, and we look forward to FDA’s review of our PMA submission."

"The CyPass micro-stent represents the next wave of innovation in the MIGS category," added co-lead investigator Dr. Steven Vold of Vold Vision in Fayetteville, Ark. "It is encouraging to see the Compass results validated through such a large, robust pivotal study. With an elegant, straightforward implantation procedure coupled with these positive clinical outcomes, the CyPass micro-stent is positioned to provide a valuable new therapeutic option for ophthalmologists treating their cataract patients suffering from glaucoma."

Filed Under: News Well, Optical/Ophthalmic, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Clinical Trials, Glaucoma, Transcend Medical Inc.

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy